A novel therapeutic approach targeting inflammation may offer new hope for patients with pancreatic cancer, according to preclinical research to be presented at the 2025 American Association for Cancer Research (AACR) Annual Meeting.
SignaBlok, a biotechnology company specializing in innovative peptide therapies, will showcase promising data on a first-in-class macrophage-restricted TREM-1 inhibitor. The research indicates the drug could potentially transform treatment strategies for pancreatic cancer and other difficult-to-treat solid tumors.
In experimental studies, the TREM-1 inhibitor demonstrated remarkable capabilities when administered after standard chemotherapy. Key findings reveal the drug prevents cancer recurrence, improves complete response rates, and enhances patient survival. Moreover, the treatment successfully reversed immunosuppression and overcame resistance to anti-PD-L1 immunotherapy.
Pancreatic cancer remains a critical medical challenge, ranking as the third leading cause of cancer-related deaths in the United States. Current statistics show a stark 5-year survival rate of merely 13% across all stages, underscoring the urgent need for innovative therapeutic approaches.
The research leverages SignaBlok’s proprietary SCHOOL technology platform, which enables the development of targeted therapies with a novel mechanism of action. Rodent studies have already indicated that the TREM-1 inhibitor is safe and well-tolerated, providing additional confidence in its potential clinical application.
Central to this approach is targeting TREM-1, a receptor that serves as an inflammation amplifier. By strategically inhibiting this receptor, researchers aim to disrupt the complex inflammatory processes that contribute to cancer progression and resistance.
SignaBlok’s findings will be presented by Dr. Alexander B. Sigalov, the company’s President and Principal Investigator, during Poster Session 52 at the AACR Annual Meeting on Monday, April 28, 2025.
The potential implications of this research extend beyond pancreatic cancer, suggesting a promising pathway for treating various inflammation-associated solid tumors. As the scientific community continues to explore innovative therapeutic strategies, SignaBlok’s approach represents a significant step toward more effective and targeted cancer treatments.
This news story relied on a press release distributed by 24-7 Press Release. Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is SignaBlok’s Novel TREM-1 Inhibitor Shows Promise in Pancreatic Cancer Treatment.